FCF Life Sciences Venture Capital Monitor – Europe 03/2022 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 03/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of  March 2022 we identify the following current VC trends in Europe:
  • In 2022, overall Life Sciences funding has reached EUR 2,880m so farTop 5 Deals exceed EUR 70m each, largest transaction amounted to EUR 500m in Doctolib (France)
  • Bpifrance dominates the Top 5 Investors (by deal volume), followed by Eurazeo (France) and General Atlantic (United States)
  • The Biotech sector received 42% of the total investment volume, no change compared to the previous month
  • Oncology dominates as the top indication of the Biotechnology sector
To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Johannes Link
Share
[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]